8-K: Immix Biopharma Stockholders Approve All Proposals at 2025 Annual Meeting, Elect Directors and Ratify Auditor

Immix Biopharma, Inc. announced that its stockholders approved all proposals at the 2025 Annual Meeting, including the election of eight directors and the ratification of Crowe LLP as the independent registered public accounting firm.

Summary

• Immix Biopharma, Inc. held its 2025 Annual Meeting on June 20, 2025, with a quorum established by 20,092,566 shares (72.1% of voting shares) present in person or by proxy.
• Stockholders elected eight individuals to serve as directors until the next annual meeting: Ilya Rachman, Gabriel Morris, Jason Hsu, Magda Marquet, Helen C. Adams, Carey Ng, Jane Buchan, and Yekaterina Chudnovsky.
• All director nominees received a significant majority of 'For' votes, with Ilya Rachman, Jason Hsu, and Yekaterina Chudnovsky receiving over 14.5 million 'For' votes each.
• Stockholders ratified the appointment of Crowe LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025, with 19,946,506 votes 'For', 47,622 'Against', and 98,438 'Abstentions'.

Sentiment

Score: 8

Explanation: The sentiment is positive as all proposals were approved by stockholders, indicating stable corporate governance and successful execution of the annual meeting agenda.

Positives

• All proposals presented at the Annual Meeting were successfully approved by the stockholders.
• A strong quorum of 72.1% of voting shares was present, indicating high stockholder engagement.
• The election of all nominated directors ensures continuity in the company's leadership.
• The ratification of Crowe LLP as the independent auditor provides assurance of continued financial oversight and compliance.

Future Outlook

The document primarily reports on past voting results and does not provide specific forward-looking statements or financial guidance beyond the term of the elected directors until the next annual meeting and the auditor's appointment for the fiscal year ending December 31, 2025.

Industry Context

This filing is a routine corporate governance update common across all publicly traded companies, reflecting the outcome of their annual stockholder meetings. It does not contain information specific to the biopharma industry trends or competitive landscape.

Corporate Governance

Stakeholder Impact

• Shareholders: Approved all proposals, including the election of directors and auditor ratification, affirming their support for the company's governance and oversight.

Next Steps

• The elected directors will serve until the next annual meeting of stockholders and until their successors are duly elected and qualified.
• Crowe LLP will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Keywords

Immix Biopharma, IMMX, SEC Filing, 8-K, Annual Meeting, Stockholder Vote, Director Election, Auditor Ratification, Corporate Governance, Biopharma